Woodcliff Lake, NJ, United States of America

Yiwen Li

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 3.5

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Woodcliff Lake, NJ (US) (2019 - 2022)
  • Woodcliff, NJ (US) (2022 - 2024)

Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Yiwen Li: Innovator in Cancer Therapeutics

Introduction

Yiwen Li is a prominent inventor based in the United States, recognized for her contributions to the field of cancer therapeutics. With a focus on innovative antibody treatments, she has made significant strides in developing therapies that target specific cancer pathways.

Latest Patents

Although Yiwen Li currently holds no patents, her latest inventions include groundbreaking concepts such as Anti-CD137 Antibodies for Combination with Anti-PD-L1 Antibodies. This invention relates to antibodies that bind to human CD137 and display agonist activity, potentially useful for treating solid and hematological tumors in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation. Another notable invention is the Checkpoint Inhibitor Bispecific Antibodies, which are heterodimeric antibodies that bind human PD-L1 and human PD-1, offering potential treatment options for cancer alongside chemotherapy and other cancer therapeutics.

Career Highlights

Throughout her career, Yiwen Li has worked with esteemed organizations, including Eli Lilly and Company and Zymeworks BC Inc. Her experience in these companies has allowed her to contribute to the advancement of cancer treatment methodologies.

Collaborations

Yiwen Li's collaborations with leading pharmaceutical companies have been instrumental in her research and development efforts. By working alongside experts in the field, she has been able to enhance the efficacy of her

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…